Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03722342
Registration number
NCT03722342
Ethics application status
Date submitted
3/07/2018
Date registered
26/10/2018
Date last updated
17/08/2022
Titles & IDs
Public title
TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma
Query!
Scientific title
A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma
Query!
Secondary ID [1]
0
0
PMC_TTAC-0001_04
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Recurrent Glioblastoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Brain
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - TTAC-0001 and pembrolizumab combination
Experimental: TTAC-0001 and pembrolizumab - TTAC-0001 and pembrolizumab combination therapy will be administered.
Treatment: Drugs: TTAC-0001 and pembrolizumab combination
Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)
Treatment groups: 3 dose levels
Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1
Cycle: 3 weeks (21 days per cycle)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Dose limiting toxicities
Query!
Assessment method [1]
0
0
The frequency and percentage of DLT will be presented by dose level
Query!
Timepoint [1]
0
0
During the first cycle (every cycle is 21 days) of treatment
Query!
Primary outcome [2]
0
0
Adverse events
Query!
Assessment method [2]
0
0
The frequency and percentage of AEs will be presented by dose level
Query!
Timepoint [2]
0
0
From the screening visit to the end of treatment visit (time of progressive disease or 2 years)
Query!
Primary outcome [3]
0
0
Immunogenicity
Query!
Assessment method [3]
0
0
Presence anti-drug antibody (ADA) will be listed
Query!
Timepoint [3]
0
0
From screening visit to end of treatment visit (time of progressive disease or 2 years)
Query!
Secondary outcome [1]
0
0
Overall response rate
Query!
Assessment method [1]
0
0
complete response (CR) or partial response (PR) by RANO criteria
Query!
Timepoint [1]
0
0
At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)
Query!
Secondary outcome [2]
0
0
Disease control rate
Query!
Assessment method [2]
0
0
complete response (CR), partial response (PR) or stable disease (SD) by RANO criteria
Query!
Timepoint [2]
0
0
At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)
Query!
Secondary outcome [3]
0
0
Progression free survival
Query!
Assessment method [3]
0
0
Period from the date of the drug administration to the disease progression time point
Query!
Timepoint [3]
0
0
From screening visit to end of treatment visit (time of progressive disease or 2 years)
Query!
Secondary outcome [4]
0
0
Overall survival
Query!
Assessment method [4]
0
0
Period from the date of the drug administration to the patient's death
Query!
Timepoint [4]
0
0
From screening visit to date of patient's death (assessed up to 2 year after end of treatment visit)
Query!
Eligibility
Key inclusion criteria
1. Diagnosed with primary glioblastoma by histopathological examination and confirmed
recurrent glioblastoma by magnetic resonance imaging (MRI) scans after completing
standard of care (Stupp protocol) concomitant temozolomide chemotherapy with
radiotherapy (CCRT)
2. At least one confirmed measurable lesion by RANO criteria
3. Karnofsky Performance Status (KPS) =80
4. A person who satisfies the following criteria in haematologic, renal, and hepatic
function tests performed within 7 days prior to screening:
1. Haematologic tests
- Absolute neutrophil count (ANC) = 1.5 x 109/L
- Platelets = 100 x 109/L
- Haemoglobin = 9.0 g/dL
2. Blood coagulation tests
- Prothrombin time (PT) = 1.5 x Upper limit of normal (ULN)
- Activated partial thromboplastin time (aPTT) = 1.5 x ULN
3. Hepatic function tests
- Total bilirubin = 1.5 x UNL
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) = 2.5 x
ULN (= 5 x ULN in case of liver metastasis)
4. Renal function test
- =1.5 × ULN or creatinine clearance (CrCl) =30 mL/min for patient with
creatinine levels >1.5 × institutional ULN
5. At least 12 weeks of expected survival time
6. The patient (or legally acceptable representative if applicable) is able and willing
to provide written informed consent for the trial
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Has a known additional malignancy that is progressing or has required active treatment
within the past 2 years. (Note: Patients with basal cell carcinoma of the skin,
squamous cell carcinoma of the skin or carcinoma in situ [e.g., breast carcinoma,
cervical cancer in situ] controlled by curative therapy are not excluded)
2. Has received prior radiotherapy within 2 weeks of start of study treatment. Patients
must have recovered from all radiation-related toxicities, not require
corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
for palliative radiation (=2 weeks of radiotherapy) to non-CNS disease
3. Has a history of (non-infectious) pneumonitis/interstitial lung diseases that required
steroids or current pneumonitis/interstitial lung disease
4. Has an active infection requiring systemic therapy
5. Uncontrolled hypertension (systolic blood pressure [SBP]> 150 or diastolic blood
pressure [DBP]> 90 mmHg)
6. Uncontrolled seizures
7. Class III or IV heart failure by New York Heart Association (NYHA) classification
8. Has oxygen-dependent chronic disease
9. Active psychiatric disorder (schizophrenia, major depressive disorder, bipolar
disorder etc.). Treated depression with ongoing antidepressant medication is not an
exclusion
10. History of abdominal fistula or gastrointestinal perforation within 6 months prior to
start of study drug
11. History of serious gastrointestinal haemorrhage within 6 months prior to start of
study drug
12. History of severe arterial thromboembolic event within 12 months of start of study
drug
13. Serious grade 4 venous thromboembolic event including pulmonary embolism
14. History of hypertensive crisis or hypertensive encephalopathy
15. History of posterior reversible encephalopathy syndrome
16. Planned surgery within 4 weeks post last dose
17. Moderate to severe proteinuria as demonstrated by urine dipstick for proteinuria =2+.
For patients with =2+ proteinuria on dipstick urinalysis, a urine protein: creatinine
(UPC) ratio will be determined, or a 24-hour urine collection will be done. Patients
with a UPC ratio <1 or a 24-hour urine protein <1 gram are eligible
18. Requiring therapeutic anticoagulation with warfarin at baseline; patients must be off
warfarin or warfarin-derivative anticoagulants for at least 7 days prior to starting
study drug; however, therapeutic or prophylactic therapy with low-molecular weight
heparin is allowed
19. Not recovered below National Cancer Institute-Common Terminology for Adverse Events
(NCI-CTCAE) grade 1 or baseline from AEs due to previous therapy (patient with = Grade
2 neuropathy or alopecia may be eligible)
20. Treatment with systemic chemotherapy, hormonal therapy, immunotherapy or biologic
therapy within 2 weeks prior to the baseline visit
21. Undergone major surgery requiring general anaesthesia or a respiratory assistance
device within 4 weeks prior to the baseline visit (within 2 weeks for video-assisted
thoracoscopic surgery [VATS] or open-and-closed [ONC] surgery)
22. Treated with other investigational drugs within 4 weeks prior to the baseline visit
for this study
23. Pregnant* or lactating females, and females/males of childbearing potential who do not
agree to a reliable and adequate method of contraception
24. A known history of severe drug hypersensitivity or hypersensitivity to a therapy
similar to the study drugs
25. Unable to participate in the trial according to the investigator's decision
26. Previous therapy with vascular endothelial growth factor (VEGF)-targeted agents
including (but not limited to) bevacizumab
27. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or
higher irAE
28. Has an active autoimmune disease that has required systemic treatment in past 2 years
(i.e., with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency) is not considered a form
of systemic treatment and is allowed
29. Known human immunodeficiency virus (HIV) infection. No HIV testing is required unless
mandated by local health authority
30. Known active hepatitis B or hepatitis C infection. No testing for hepatitis B and
hepatitis C is required unless mandated by local health authority
31. Have received a live vaccine within 30 days prior to enrollment. Seasonal flu vaccines
that do not contain live virus are permitted
32. Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior
to enrollment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/01/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/09/2022
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
9
Query!
Recruitment in Australia
Recruitment state(s)
VIC,WA
Query!
Recruitment hospital [1]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [2]
0
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [2]
0
0
6009 - Nedlands
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
PharmAbcine
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to
establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in
combination with pembrolizumab in patients with recurrent glioblastoma.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03722342
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03722342
Download to PDF